Valneva SE VALN
NASDAQ VALN
$6.95 -0.11 (-1.63%)
As of: Sep 4, 2026 · 12:37 PM EDT

Valneva SE (VALN) Consolidated Net Income (2021 - 2026)

Valneva SE (VALN) posted Consolidated Net Income of -$38.5 million for Q1 2026, up 33.98% sequentially from -$58.3 million in Q4 2025, and down 240.92% YoY from $27.3 million in Q1 2025.

Analysis

Valneva SE (VALN) Consolidated Net Income (2021 - 2026) Analysis & Trends

Valneva SE has reported Consolidated Net Income for 6 years, with the latest figure at -$38.5 million in Q1 2026.

  • Quarterly Consolidated Net Income fell 240.92% year-over-year to -$38.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$162.5 million (down 83.46% YoY) and the FY2025 annual result came in at -$134.1 million, down 849.77% from the prior year.
  • Consolidated Net Income climbed to -$38.5 million in Q1 2026 per VALN's latest filing, from -$58.3 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $2.2 billion in Q4 2022 and troughed at -$2.1 billion in Q3 2022.
  • A 5-year average of -$25.1 million and a median of -$28.1 million in 2022 frame the typical range for Consolidated Net Income.
  • The widest YoY moves for Consolidated Net Income: up 1017.53% in 2022, down 1033.07% in 2022.
  • Over 5 years, Consolidated Net Income stood at $2.2 billion in 2022, then slumped by 101.79% to -$38.8 million in 2023, then slipped by 14.82% to -$44.5 million in 2024, then sank by 30.86% to -$58.3 million in 2025, then jumped by 33.98% to -$38.5 million in 2026.
  • According to Business Quant data, Consolidated Net Income over the past three periods registered -$38.5 million, -$58.3 million, and -$52.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Vertex Pharmaceuticals 139.62 Bn 131.77 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.73 Bn 77.73 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.53 Bn 58.35 Bn 1.37 Bn 601.00 Mn
4 Moderna 58.23 Bn 53.09 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - -644.37 Mn
6 BeOne Medicines 40.03 Bn 34.93 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.50 Bn 32.19 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.52 Bn 27.68 Bn - 81.49 Mn
9 Insmed 27.46 Bn 26.30 Bn 358.27 Mn -13.27 Mn
10 Valneva SE 584.00 Mn 442.75 Mn 1.86 Mn -37.58 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -37.58 Mn
Mar 31, 2026 -35.62 Mn
Dec 31, 2025 -58.29 Mn
Sep 30, 2025 -54.74 Mn
Jun 30, 2025 -13.62 Mn
Mar 31, 2025 -6.61 Mn
Dec 31, 2024 -39.59 Mn
Sep 30, 2024 -9.77 Mn
Jun 30, 2024 -27.21 Mn
Mar 31, 2024 64.01 Mn
Dec 31, 2023 -26.20 Mn
Sep 30, 2023 -31.43 Mn
Jun 30, 2023 -26.39 Mn
Mar 31, 2023 -19.71 Mn
Dec 31, 2022 -52.65 Mn
Sep 30, 2022 72.80 Mn
Jun 30, 2022 -151.43 Mn
Mar 31, 2022 -28.10 Mn
Dec 31, 2021 201.46 Mn
Sep 30, 2021 -185.83 Mn